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The most devastating aspect of cancer is the emergence of metas-
tases. Thus, identification of potentially metastatic cells among a
tumor cell population and the underlying molecular changes that
switch cells to a metastatic state are among the most important
issues in cancer biology. Here we show that, although normal
human colonic epithelial cells lack the glycosphingolipid globotri-
aosylceramide (Gb3), this molecule is highly expressed in meta-
static colon cancer. In addition, a subpopulation of cells that are
greatly enriched in Gb3 and have an invasive phenotype was
identified in human colon cancer cell lines. In epithelial cells in
culture, Gb3 was necessary and sufficient for cell invasiveness.
Transfection of Gb3 synthase, resulting in Gb3 expression in non-
cancerous polarized epithelial cells lacking endogenous Gb3, in-
duced cell invasiveness. Furthermore, Gb3 knockdown by small
inhibitory RNA in colon cancer epithelial cells inhibited cell inva-
siveness. Gb3 is the plasma membrane receptor for Shiga toxin 1.
The noncatalytic B subunit of Shiga toxin 1 causes apoptosis of
human colon cancer cells expressing Gb3. Injections of the B subunit
of Shiga toxin 1 into HT29 human colon cancer cells engrafted into
the flanks of nude mice inhibited tumor growth. These data
demonstrate the appearance of a subpopulation of Gb3 containing
epithelial cells in the metastatic stage of human colon cancer and
suggest their possible role in colon cancer invasiveness.
metastases  invasion  filopodia
Colorectal cancer is the second leading cause of cancer death inthe U.S. (1, 2). The high mortality associated with colorectal
cancer is related to its ability to spread beyond the large intestine
and to invade distant organs. One route to improve understanding
of the molecular mechanisms of metastasis is by the identification
of genes that are differently expressed during cancer progression
andor are responsible for acquisition of the metastatic phenotype.
Although many molecular factors have been identified as contrib-
uting to metastases and represent potential targets for treatment
(3), much remains to be learned about the biology of themetastatic
process. Aberrant glycosylation, which has been observed in essen-
tially all types of human cancers during cancer progression into the
metastatic stage, is an example of a metastases-related change that
is based, in part, on altered gene expression (4).
Aberrant glycosylation due to tumor transition into an invasive
stage is also associated with changes in glycosphingolipid (GSL)
composition. GSLs are abundant in the outer leaflet of plasma
membranes of nearly all eukaryotic cells and have many diverse
functions (5, 6). GSLs serve as receptors for viral and bacterial
toxins, and microbial infections may be mediated by interactions of
host GSLs with microbial membrane proteins. GSLs at the cell
surface modulate transmembrane signal transduction by influenc-
ing protein kinases associated with growth factor receptors and
PKC. GSL–GSL interactions and formation of so-called glycosyn-
apses appear to provide the basis for a specific cell recognition
system independent of the fibronectinintegrin or surface lectin
systems (7). Surprisingly large numbers of tumor-associated anti-
gens have been identified as GSLs. Altered GSL structures and cell
surface expression patterns are associated with invasive phenotypes
of some experimental tumors (7). Thus, it is well established that
GM3 inhibits cell motility and invasiveness in bladder tumors (8).
Gangliosides Gt1b, GD1A, GM3, and GM1 inhibit cell proliferation
and epidermal growth factor receptor tyrosine phosphorylation (9,
10), whereas depletion of Gt1b and GM3 by sialidase overexpression
facilitates epidermal growth factor receptor phosphorylation and
cell migration (10). Oppositely, a different GSL, Gb5, strongly
enhances motility of breast cancer cells (11).
We have now identified a form of abnormal glycosylation that
correlates with the development of human colon cancer metastasis.
Globotriaosylceramide (Gb3) is expressed in metastatic colon can-
cer and is virtually absent from normal colonic epithelial cells. We
found that Gb3-expressing colon cancer cells represent a potentially
invasive subpopulation. Molecular manipulation to increase Gb3
expression converts noninvasive epithelial cells into cells with an
invasive phenotype, and the molecular alterations that lead to Gb3
up-regulation appear to be sufficient for this transformation. To
explore the role of Gb3 in the growth of human colon cancer cell
lines established from metastatic lesions, advantage was taken of
the fact that Gb3 serves as a receptor (12, 13) for the noncatalytic
B subunit of Shiga toxin 1 (Stx1B). As in other cells (14), the
selective binding and uptake of the Stx1B by Gb3-positive Caco-2
cells is shown to cause apoptosis. We also show that intratumoral
injection of Stx1B inhibited colonic tumor growth in the nude
mouse model.
Materials and Methods
Cell Culture and Human Tissue. Caco-2, T84, OK, and HT29 cells
were from the American Type Culture Collection. Samples of
archived frozen human tissue included normal distal and proximal
colon (n  15), nonmalignant colonic adenomas (n  3), colon
cancer without metastases (n  3), primary lesions of metastatic
colon cancer (n 5), and colon cancer metastases in liver (n 2).
This study was exempted under the Code of Federal Regulations
Title 45 Section 46.101(b) by the Hopkins Institution Review
Board.
Fluorescence Microscopy. To evaluate the distribution of Gb3, cells
grown on glass coverslips were incubated for 1 h with 0.5 gml
Stx1B–Alexa Fluor 488 (Stx1B–488). All experiments, except im-
munofluorescence, were performed on living cells mounted in a
perfusion chamber (Warner Instruments, Hamden, CT) with
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Hepes buffer, pH 7.4, at 37°C on themicroscope stage, as described
(SupportingMaterials andMethods, which is published as supporting
information on the PNAS web site) (15). The quantification of the
relative amount of Gb3 in cells and tissue samples is described in
detail in Supporting Materials and Methods.
Chemoinvasive Assay. Chemoinvasion was assayed in cell culture
chambers by using 24-mm Transwell inserts with 8-m pore mem-
branes (Corning) as described in ref. 16. The membrane bottoms
were precoated with 1 gml laminin. Caco-2 cells or nontrans-
formed renal proximal tubule OK cells were seeded on the top
surface of the filters. After incubation for 24, 48, or 72 h, cells on
both sides of the membrane were stained, and 0.5-m confocal
optical sections were taken through the whole membrane thickness
with a100 objective lens. The distribution of cells on the top and
bottom surfaces of the membrane and numbers of cells were
analyzed with METAMORPH and VOLOCITY (Improvision, Lexing-
ton, MA) image processing software. Five fields were examined in
each membrane.
Gb3 Synthase Knockdown. To affect the silencing of a specific gene,
we used the pSUPER vector ligated with small inhibitory RNA
(siRNA) oligonucleotides (17). By using the OLIGOENGINE siRNA
design tool (OligoEngine, Inc., Seattle), five Gb3 synthase cDNA
coding regions suitable for RNA interference were chosen and
DNA oligos were obtained. Caco-2 cells are difficult to transfect
with high efficiency by using lipophylic agents. To overcome this
problem, an adenoviral vector was constructed in collaboration
with the Johns Hopkins Adenoviral Preparation, Purification, and
Titering Core Facility, in which the pSUPER siRNA shuttle vector
with cDNA–GFP (to monitor the efficiency of viral infection) was
ligated. Exposure of 50% confluent Caco-2 cells to 1.3  1010
particles per ml of adenovirus led to 50% GFP-positive cells, and
this percentage did not increase significantly with higher doses of
the virus. The Gb3 synthase cDNA oligo forward and reverse
sequences gatccccCTTCCTGTTCATGTGTGCTCGttcaa-
gagaCGAGCACATGAACAGGAAGtttttggaaa and agcttttc-
caaaaaCTTCCTGTTCATGTGCTCGtctcttgaaCGAGCACATG-
AACAGGAAGggg were the most effective in terms of inhibition
of Gb3 synthesis, which was monitored by both specific Stx1B
binding and CD77 mAb. The monolayers were inspected by fluo-
rescence microscopy, and all GFP-positive cells were Gb3-free by
48 h after infection.
For siRNA control experiments, pSUPERvector with scrambled
RNA (scRNA) duplex (catalog no. D-1200-05, Dharmacon Re-
search, Layfayette, CO) was engineered. Caco-2 cells were infected
with 1 1010 to 2 1010 particles per ml scRNA adenovirus. After
48 h, cells were used for high-performance thin-layer chromatog-
raphy (HPTLC) to assess the changes in Gb3 content or for protein
expression assay by Western blot.
Laser Capture Microdissection (LCM), GSLs Extraction, and HPTLC. To
collect a cancer cell population enriched in epithelial cells, the tissue
Fig. 1. Gb3 is expressed in the primary lesions of human metastatic colon cancer and in liver metastases. (A) Normal colonic tissue immunostained against -catenin
(red) and Stx1B–488 (green) to mark Gb3. (B) Normal colonic tissue labeled with CD77 mAb against Gb3 (red) and cholera toxin B subunit to detect GSL GM1 (green).
Note that cells in lamina propria but not epithelial cells are Gb3-positive (n 54 fields of view). (C) Noncancer colonic adenoma immunolabeled against-catenin (red)
and Stx1B–488 (green) for Gb3 (n 12 fields of view). Note that erythrocytes (yellow, do not have nuclei) but not epithelial cells are Gb3-positive. (D) Nonmetastatic
colon cancer tissue labeled against pankeratin to detect epithelial cells (red) and Gb3 by Stx1B–488 (green) (n  12 fields). (E) Metastatic colon cancer tissue
immunostained against actin (green) and Gb3 marked by Stx1B–568 (red). (F) Hematoxylineosin staining corresponding to sample in E (n 29 fields). (G) Colon cancer
metastases into the liver (n 17 fields) labeled with Stx1B–488 (green) and mAb against -catenin (red). (H) Normal liver tissue (n 10 fields) immunostained with
Stx1B–488 (green) and against -catenin (red). Nuclei are stained with Hoechst dye (blue). (I and J) Tissue sample of hematoxylin-stained, nonmetastatic colon cancer
before LCM (I) and after LCM when cancer epithelial cells were collected (J). (K) HPTLC shows the absence of Gb3 in epithelial cells collected by LCM from nonmetastatic
colon cancer (lane 1) as inD, and Gb3 presence in metastatic colon cancer (lane 2) as inE. Lane 3 shows a mixture of purified markers (10gml Gb3 and 5gml LacCer).
(L) Relative amount of Gb3 (percentages) in epithelial cells in human tissue normalized to normal colon or liver. Bars: 1, normal colon; 2, noncancer adenomas; 3,
nonmetastatic colon cancer; 4, primary lesion of metastatic colon cancer; 5, colon cancer metastases into liver; 6, normal liver. The relative amount of Gb3 in normal
colonic and liver tissue was calculated from analysis of 8-bit fluorescence images as an average of fluorescence intensity per field of view and presented as 100% SE.
TheamountofGb3 incancer tissuewascalculatedsimilarlyandexpressed inpercentages relative tocontrol. TherelativeamountofGb3 significantly (P0.05) increased
in metastatic tissues compared with normal colon and liver, respectively.
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samples were hematoxylin stained, vacuum dried, and subjected to
LCM (P.A.L.M. Microlaser Technologies, Bernried, Germany) by
following manufacturer’s protocols. To detect Gb3 in cancer epi-
thelial cells, the LCM collected cells from two cases of nonmeta-
static and two cases ofmetastatic colon cancers or fromCaco-2 cells
infected either with small inhibitory Gb3 or scRNA were subjected
to HPTLC as described in detail (Supporting Materials and Meth-
ods) (18–20).
Nude Mouse Xenograft Model. The growth of HT29 human colonic
cancer cells injected into the flanks of nude mice was determined
with or without intratumor injection of a fixed amount of Stx1B
administered every 2 days starting 7 days after tumor injection.
Initially, effects of s.c. flank injections of various amounts of Stx1B
were determined on nude mouse mortality and on liver, small
intestine, and kidney histology at the light microscopy level. All
experiments were conducted according to a protocol approved by
the JohnsHopkinsUniversity School ofMedicineAnimalCare and
Use Committee.
Statistics. Data are presented as mean  SEM. Significance was
determined by using Student’s t test, and P 0.05 were considered
statistically significant.
Results
Gb3 Is Expressed in Colon CancerMetastases but Not in Normal Colonic
Tissue, Noncancer Adenomas, and Nonmetastatic Colon Cancer. To
begin characterizing which types of colon cancer express Gb3,
immunofluorescence staining was performed with CD77 Ab
against Gb3 or fluorescently labeled Stx1B, which binds specifically
toGb3 (21).Gb3 was not expressed in normal colonic epithelial cells
(Fig. 1 A and B), nonmalignant colonic adenomas (Fig. 1C), or
nonmetastatic primary colon cancers (Fig. 1D). In contrast, as a
positive control, another GSL GM1, the cholera toxin B subunit
receptor, was readily detectable on the apical surface of colonocytes
(Fig. 1B). Gb3-positive cells were present in some cells in the lamina
propria (Fig. 1 A and B) and in erythrocytes (Fig. 1C). In contrast,
high levels of Gb3 were expressed in epithelial cells in primary
lesions of metastatic colon cancers and in the colon cancer metas-
tases to the liver (Fig. 1E–G). There was no detectable level of Gb3
in normal hepatocytes (Fig. 1H). To confirm the data gained by
immunofluorescence, cancer cells from primary lesions of non-
metastatic colon cancer (Fig. 1 I and J) or from metastatic samples
were collected by LCM. LCMwas done to decrease contamination
by erythrocytes, endothelial cells, or inflammatory cells, which are
known to express Gb3 (22, 23) (Fig. 1). Collected cells were
subjected to HPTLC, which showed the presence of Gb3 in met-
astatic colon cancer samples (Fig. 1K) but its virtual absence in
nonmetastatic samples. In contrast, lactoceramide (LacCer), a
precursor for many GSLs, including Gb3, was present in both types
of samples. The relative amount of Gb3 in tissue samples was
estimated from immunofluorescence images of tissue double-
labeled with Stx1B or CD77 mAb to detect the Gb3 and pankeratin
mAb and to ensure that exclusively epithelial cells were included in
the analysis. Quantification of Gb3 fluorescence intensity, which
corresponds to the relative amount of Gb3 in the sample, showed
that Gb3 is up-regulated in primary lesions of metastatic colon
cancer tissue 300% compared with the background autofluores-
cence of normal colonic epithelial cells, tubular adenomas, and
nonmetastatic cancers (Fig. 1L). Similarly, Gb3 fluorescence inten-
sity in colon cancer metastases to the liver was elevated 300%
compared with the normal liver (Fig. 1L). This significant Gb3
elevation in metastatic colon cancer caused us to examine the
potential role of Gb3 in development of tumor invasiveness.
Colon Cancer Cells with Elevated Gb3 Have a Migratory Phenotype.
Human intestinal epithelial Caco-2, T84, and HT29 cells derived
from metastatic colon cancer were examined by immunofluores-
cence microscopy and FACS for the presence of Gb3-expressing
cells. When 50–70% confluent, two subpopulations of cells were
detected in each cell line: one with or without trace amounts of Gb3
and the other with a high amount of Gb3. The percent of Gb3-
expressing cells was different in the three cell types and only 5%
of T84 cells, 50% of Caco-2 cells, and 90% of HT29 cells were
Gb3-positive. In all three cell types, Gb3-containing cells were
mostly concentrated at the leading edge of cell islands. Moreover,
cells enriched in Gb3 demonstrated a migratory phenotype and
formed filopodia (Fig. 2A,C, andD). In Caco-2 cells (Fig. 2A), the
filopodia were very thin (0.2–0.5 m), variable in number (up to
50 on a single cell), and beaded, and they contained Gb3. The
filopodia could exceed 2- to 10-fold the epithelial cell diameter and
projected in the direction of monolayer growth and cell spreading.
In all three cell lines, there was a strong correlation between the
amount of Gb3 and appearance of filopodia. Cells that formed
filopodia were significantly enriched in Gb3 compared with neigh-
boring cells without filopodia from the same leading edge (Fig. 2 A
andD). Quantitative analysis of fluorescence intensity of 11 Caco-2
cells with and without filopodia showed that cells with filopodia
Fig. 2. Filopodia-containing cells are present at the leading edge of a living
colon carcinoma monolayer detected by staining of the GSL Gb3. (A) x–y plane
from 3D reconstruction of fluorescent confocal optical sections of represen-
tative Caco-2 cells with Gb3-containing filopodia marked by Stx1B–488. Filop-
odia and filopodia-containing cells are significantly enriched in Gb3-positive
cells compared with the rest of the cells from the leading edge. (Scale bar, 10
m.) (B) x–z projection from 3D reconstruction of confocal optical sections of
representative Caco-2 cell with Gb3-containing filopodia, which is significantly
taller than adjacent cells in the monolayer. (Vertical scale bar, 25 m.) (C)
Gb3-enriched filopodia-containing HT29 cells (blue, nuclei stained by
Hoechst). (D) Gb3-positive cells with filopodia on the leading edge of T84
monolayer (red, Cyto7 dye). (E) Relative amount of Gb3 normalized per pixel
in Caco-2 cells. Bars: 1, without filopodia; 2, with filopodia (P  0.05). (F) The
heights of Caco-2 cells. Bars: 1, non-filopodia-containing cells; 2, Gb3-up-
regulating, filopodia-containing cells (P  0.05 compared with bar 1).
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express at least 3- to 5-fold more Gb3 per unit of surface area than
cells without them (Fig. 2E). Average pixel intensity was 238  18
gray levels in filopodia-containing cells vs. 52  10 gray levels in
cells without filopodia (P  0.05). The filopodia-containing cells
also have larger cell bodies (Fig. 2B). Measurement of the height
of 20 filopodia-containing cells showed (Fig. 2F) that they are
3-fold taller than non-filopodia-containing cells (33  6 m vs.
7  2 m, P  0.05).
Cells Containing Gb3 and Filopodia Are Invasive. The appearance of
cells with filopodia is consistent with their involvement in cell
spreading, migration, or invasiveness. Because Gb3-enriched filop-
odia-containing cells were detected in colonic cancer cell lines and
because epithelial cells with higher amounts of Gb3 were an
exclusive feature of metastatic colonic cancer, we hypothesized that
these cells might represent an invasive pool. To test this hypothesis,
we applied a standardized chemoinvasive assay (16) that correlates
with metastatic ability in vivo (24). In this assay, the movement of
Caco-2 cells across a filter treated from the bottom side with
laminin, a chemoattractant, was monitored. This assay demon-
strated that only filopodia-containingGb3-enriched cells migrate to
the bottom surface of the filter and do so by the initial movement
of filopodia through the filter pores (Fig. 3 A–D).
Filopodia-containing cells that migrated through the filter cre-
ated a confluent monolayer of cells. Attempts to clone Gb3-
enriched Caco-2 cells resulted in formation of cell monolayer with
only50%Gb3-containing cells, similar to that in wild-typeCaco-2
monolayers. Analysis of the expression of theGb3 synthasemRNA,
an enzyme responsible for Gb3 synthesis (22, 25), in the subpopu-
lation of Gb3-negative vs. Gb3-up-regulating Caco-2 cells (Fig. 6 A
and B, which is published as supporting information on the PNAS
web site) showed the presence of Gb3 synthase mRNA in both cell
types, with only a nonsignificant 1.4-fold elevation in Gb3-enriched
cells (Supporting Materials and Methods). This result indicates that
the invasive subpopulation of cells does not occur because of the
differential expression of theGb3 synthase gene but, rather, because
of the regulation of protein andor lipid expression by uncharac-
terized signal transduction mechanisms.
Gb3 Is Necessary for Colon Cancer Cell Invasiveness. One way to
further explore the role of Gb3 in invasiveness is to inhibit Gb3
synthesis in colon cancer cells and determine the impact on cell
invasiveness. There are no specific inhibitors of Gb3 synthesis (26).
Thus, to address this question, we used siRNA (17) to knock down
the Gb3 synthase gene (siGb3). For these experiments, Caco-2 cells
were infected with adenovirus containing siGb3 to silence the Gb3
synthase gene and thus prevent Gb3 synthesis (Fig. 3E). To ensure
Fig. 3. Gb3 is necessary for the development of the invasive cell phenotype:
chemoinvasive assay. Confocal optical sections of Caco-2 and OK cells grown
on Transwell filters from the top surface to bottom. Green indicates cells that
were stained with Stx1B–488. (A) Confluent monolayer of Caco-2 cells on the
top of filter. (B) Section through the filter. (C and D) Gb3-enriched, filopodia-
containing cells invading the bottom surface of filter (note the initial appear-
ance of filopodia, arrows). (E) Caco-2 cells infected with Gb3 synthase siRNA
plus GFP (green) do not have Gb3 and do not bind Stx1B–568 (red) 72 h after
infection. Note cells are either red or green. (F) x–z section through the filter
shows that these GFP-positive, Gb3-free cells do not invade the bottom surface
of the filter because of siGb3. (G) HPTLC detected a decrease in the relative
amount of Gb3 in siGb3-infected Caco-2 cells (lane 1) vs. scRNA-infected cells
(lane 2). Lane 3 shows the standard, which contains a mixture of 30 g of
purified LacCer and 30 g of Gb3.
Fig. 4. Gb3 is sufficient for the development of the invasive cell phenotype:
chemoinvasive assay. (A) Subconfluent OK cells labeled by Cyto7 dye (red) do
not express Gb3, do not bind Stx1B–488, and do not form filopodia on the
leading edge. (B) OK cells do not invade the bottom surface of the membrane
but form only a monolayer on the top surface of the filter. (C) OK cells
transfected with Gb3 synthase bind Stx1B–488 and form Gb3-enriched filop-
odia (green). (D) Only Gb3-expressing OK cells (green) invaded the bottom
surface of the filter. (E) RT-PCR detects the presence of 428 bp of Gb3 synthase
mRNA in OK cells transfected with human Gb3 synthase cDNA; Lanes: 1,
control, nontransfected OK cells do not express Gb3 synthase; 2, Gb3 synthase
mRNA is present in transfected OK cells, which express Gb3; 3, a base pair
standard, with arrows indicating 400- and 500-bp markers.
19090  www.pnas.orgcgidoi10.1073pnas.0506474102 Kovbasnjuk et al.
the specificity of siGb3 knockdown, Caco-2 cells were also infected
with scRNA-containing viral vector. The effect of siGb3 and
scRNA on the relative amount of Gb3 was assessed 48 h later by
usingHPTLC (Fig. 3G). The amount of Gb3 in siGb3 infected cells
was 57  18%, significantly (P  0.05, n  3) lower than that in
scRNA infected cells (100  21%). In contrast, the amount of
-catenin, adenomatous polyposis coli protein, epithelial sodium-
proton exchanger 2, and GAPDH (Fig. 7, which is published as
supporting information on the PNAS web site) did not differ in the
two types of infection.
For the chemoinvasive assay, confluent Caco-2 cells grown on
Transwell membranes were infected with adenovirus containing
siGb3 and GFP. All cells that migrated through the pores in the
membrane before the infection were scraped off 24 h after infec-
tion. The numbers of Gb3-positive cells vs. the GFP-positive,
Gb3-free cells that migrated through the filter were counted 72 and
120 h after infection. Analysis of 15 fields of view in three
membranes showed that from 3 to 10 cells per field migrated
through the filter 72 h after infection and all of them were
Gb3-positive (Fig. 3F). In contrast, all GFP-positive, Gb3-free cells
remained on top of the membrane and did not migrate, even 120 h
after infection (Fig. 3F). We conclude that Gb3 expression is
necessary for Caco-2 cells to invade and that down-regulation of
Gb3 by inhibition of Gb3 synthase through siGb3 prevents cell
migration.
Gb3 Is Sufficient for Epithelial Cell Invasiveness. To test whether Gb3
expression is sufficient for epithelial cells to invade, we studied OK
cells, which do not endogenously express Gb3, do not bind Stx1B
(Fig. 4A), and are not invasive based on the fact they do notmigrate
through the membrane pores (Fig. 4B). These cells were transiently
transfected with a Gb3 synthase cDNA (Supporting Materials and
Methods) (22), shown to express Gb3 synthase (Fig. 4E), and then
tested by chemoinvasive assay. Gb3-expressing OK cells formed
Gb3-positive filopodia on the leading edge of growing monolayers
(Fig. 4C) similar to that in T84, Caco-2, and HT29 cells. Moreover,
as shown by the chemoinvasive assay (Fig. 4D), OK cells now
penetrated through the filter. Importantly, only Gb3-positive OK
cells penetrated through the filter, whereas cells without Gb3 from
the same monolayer (Fig. 4D) and control cells transfected only
with empty vector did not migrate through the filter at all and
behaved similarly to the nontransfected cells (Fig. 4B).
B Subunit of Shiga Toxin Selectively Kills Gb3-Positive Colon Cancer
Cells in Cell CultureModels andMouse Xenographs. It has been shown
that the noncatalytic Stx1B triggers apoptosis of Gb3-expressing
Burkitt’s lymphoma cells (14). To test whether Stx1B selectively
causes apoptosis in Gb3-positive colonic cells, T84 cells were
exposed to Stx1B for up to 168 h. Mitochondria were monitored as
a viability control by using tetramethylrodamine (7, 27). After 24 h
of exposure to Stx1B, virtually all T84 cells that lacked Gb3 and,
thus, did not internalize Stx1B had active mitochondria (Fig. 8A,
which is published as supporting information on the PNAS web
site). However, cells that accumulated Stx1B had inactive mito-
chondria. Incubation ofT84monolayerswith Stx1B for longer times
led to elimination of Gb3-positive cells (Fig. 8B). In contrast, in the
same monolayer, cells that did not take up Stx1B had active
mitochondria and survived. In addition, OK cells, which do not
express Gb3, were resistant to Stx1B-mediated apoptosis (Fig. 8 C
and D). Stx1B-mediated apoptosis of Caco-2 cells was also con-
firmed by the DNA-laddering assay (Fig. 8E) (28). We conclude
that Stx1B selectively kills Gb3-expressing cells.
To test whether Stx1B affects growth of colonic tumors that
contain Gb3, we used the nude mouse xenograph model (29). The
nontoxic dose of Stx1B was first determined in mice (two each)
injected s.c. with Stx1B 10 gkg, 50 gkg, 100 gkg, and 200
gkg. By day 20 after the Stx1B injection, none of the animals died
or appeared ill. Thesemicewere euthanized byCO2 inhalation. The
liver, small intestine, and kidney were shown to be histologically
normal (data not shown). Then nude mice (n  10 animals) were
injected s.c. in their flanks with 1 107 HT29 human colon cancer
cells. When tumors reached 0.3 cm in diameter (7 days after
injection), mice were divided into two groups: the control group
(n  5 mice), in which tumors were injected with PBS only, and a
test group, in which tumors on one flank were injected every other
day with a nontoxic dose of Stx1B (50 gkg, n  6 mice) and
tumors on the other flank were injected with an equal volume of
PBS. Animals were monitored over 7 weeks, by which time some
tumors reached1.5 cm size, and the animals had to be euthanized
according to our animal protocol. As shown in Fig. 5A, Stx1B
injections significantly inhibited tumor growth in nude mice. Ex-
amination of tumors for the presence of apoptotic cells using the
TUNEL assay (28) showed that there were many apoptotic cells in
Stx1B-injected tissue (Fig. 5B), whereas only a few apoptotic cells
per tumor were detected in tumors injected with PBS (Fig. 5C).
These data show that the B subunit of Stx1 alone causes apoptotic
death of Gb3-positive human colon cancer cells.
Discussion
We have identified a subpopulation of invasive colon cancer cells
based on molecular and phenotypic characteristics. Analysis of
metastatic human colon cancer tissue samples showed that signif-
icant up-regulation of the GSL Gb3 was associated with develop-
ment of metastasis. A similar subpopulation of cells with high levels
Fig. 5. An example of inhibition of HT29 colon cancer cell tumor growth in
nude mice by Stx1B. (A) HT29 tumor on one flank was injected with Stx1B,
whereas the other flank was injected with PBS. Nontreated tumor (black
squares) substantially outgrew Stx1B-treated tumor (red dots), which stopped
increasing in size 7 days after the beginning of Stx1B injections. (B) TUNEL
(green) staining of HT29 tumor injected with Stx1B shows that Stx1B caused
apoptotic death of tumor cells; cell nuclei stained by propidium iodide are red.
(C) HT29 tumor not treated with Stx1B does not have TUNEL-positive green
cells. Orange is an overlay color caused by the yellow autofluorescence by
tumor cells and their labeling by propidium iodide (red). The dark area is
mouse tissue that surrounds the tumor.
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of Gb3 expression and a migratory phenotype was found in three
colon cancer cell lines established from metastatic human colon
cancers. These cell lines may serve as a model for invasiveness
development in a cancer cell population. It has been shown that the
epithelial cells in human colon lack detectable Gb3 (23, 30). This
finding is in good agreement with our data that Gb3 is virtually
absent from normal colonic epithelial cells but is present in colon
cancer in its metastatic stage.
Gb3 has been associated with other human cancers and was
identified as the Burkitt’s lymphoma antigen (31). Elevated expres-
sion of Gb3 was also detected in astrocytoma cell lines (32) and in
several highly metastatic types of human tumors, including ovarian
and breast cancers (33). Significant Gb3 accumulation was also
previously reported in testicular seminoma, which correlated with
the metastatic potential (34, 35). These data support our finding
that Gb3 expression is a marker for colonic epithelial tumor cell
transformation from primary cancer into the metastatic stage and
indicate that several types of invasive tumors may have common
mechanisms for metastasis.
Mechanistic studies of the role of Gb3 in metastases were
performed on cell culture models. Our data demonstrate that Gb3
overexpression is necessary and sufficient for the appearance of
cells with an invasive phenotype. In colon carcinoma epithelial cells,
the presence of Gb3-containing filopodia correlates with cell inva-
siveness. Filopodia are used to penetrate through the permeable
support in a chemoinvasive assay. Importantly, elimination of Gb3
from colon cancer cells by Gb3-synthase siRNA knockdown, which
was verified by the Stx1B binding assay, completely inhibited cell
migration. This result shows that Gb3 is necessary for cell invasive-
ness. Introduction of human Gb3-synthase into nontransformed,
noninvasive OK cells that do not synthesize endogenous Gb3
inducedGb3 and converted noninvasive epithelial cells into invasive
cells. Thus, the presence of Gb3 was also sufficient to induce the
invasive phenotype in nontransformed cells.
Failure of Caco-2 cells to maintain the migratory phenotype
when Gb3-enriched cells separated by FACS were cultured shows
that Gb3-enriched invasive cells do not represent separate clones.
This result indicates that changes in signal transduction pathways,
which lead to Gb3 expression due to some as yet unknown mech-
anisms, rather than genetic alterations alone, are responsible for
appearance of the invasive pool among the population of colon
cancer cells.
Gb3 expression can be driven by several molecular mechanisms
that do not exclude but rather complement each other. One
possibility is that the enzyme Gb3 synthase (1,4-galactosyltrans-
ferase), which catalyzes the transfer of galactose to LacCer, and
produces Gb3, is significantly up-regulated during cancer progres-
sion from the noninvasive stage into the invasive stage. HumanGb3
synthase has recently been cloned (22, 25). Although expression of
Gb3 synthase has not yet been reported in metastatic vs. normal
colonic epithelial tissue using gene arrays (Oncomine Cancer array
database), the absence of a significant difference in the amount of
Gb3 synthase mRNA between Caco-2 with up-regulated Gb3 and
Caco-2 without a detectable amount of Gb3 make this mechanism
very unlikely to be responsible for the appearance of Gb3-positive
cancer epithelial cells. Othermechanisms, such as differences in the
amounts of Gb3 synthase enzyme or its activity, may be responsible
for the transition of noninvasive colon cancer cells into invasive
andor metastatic cells.
Gb3 is best known as the receptor for the B subunit of Shiga toxin
1. Our data show that, similarly to that in Gb3-positive Burkitt’s
lymphoma cells (14), Stx1B selectively kills the subpopulation of
Gb3-up-regulating colonic epithelial cells, which possess invasive
potential. Next, we tested whether the ability of Stx1B to cause
apoptosis might be used against colon cancer tumors grown in nude
mice. Treatment of HT29 cell tumors in nude mice with Stx1B
substantially inhibited tumor growth compared with nontreated
control tumors, and, after10 days, Stx1B treatment stabilized the
tumor size, whereas nontreated tumors continued to increase in
size. Thus, application of Stx1B or Stx1B linked to other more
potent antitumor agents might be an approach to target the specific
Gb3-expresing subpopulation of cells in human metastatic colon
cancers.
In summary, the expression of the GSL Gb3 strongly correlates
with the metastatic potential of human colon cancer. Gb3-enriched
colon cancer cells represent an invasive subpopulation, and Gb3
expression is necessary and sufficient for this invasiveness in cell
culture models. The overexpression of Gb3 makes it a possible
marker for detection of a potentially invasive cell subpopulation in
colon cancer.
We thank Drs. Raben and Schnaar for assistance with HPTLC exper-
iments; Dr. Clausen (University of Copenhagen, Copenhagen) for Gb3
synthase pcDNA3.1 vector; Drs. Caterina, Nealen, and Agami for
providing the pSUPER adenoviral construct with scRNA; and
Oksana Gutsal for LCM cell preparations. This work was supported by
National Institutes of Health Grants RO1DK58928, R24DK064388 (to
the Hopkins Basic Research Digestive Disease Development Core
Center), and P30DK 34928 (to the Center for Gastroenterology Re-
search on Absorptive and Sectretory Processes).
1. Gorlick, R. & Bertino, J. (1999) Semin. Oncol. 26, 606–611.
2. Yokota, J. (2000) Carcinogenesis 121, 497–503.
3. Srivastava, S., Verma, M. & Henson, D. E. (2001) Clin. Cancer Res. 7, 1118–1126.
4. Ridley, A. (2000) Nature 406, 466–467.
5. Hakomori, S. (1989) Adv. Cancer Res. 52, 257–331.
6. Hakomori, S. (1996) Cancer Res. 56, 5309–5318.
7. Hakomori, S. (2001) Adv. Exp. Med. Biol. 491, 369–402.
8. Kawamura, S., Ohyama, C., Watanabe, R., Satoh, M., Saito, S., Hoshi, S., Gasa, S.
& Orikasa, S. (2001) Int. J. Cancer. 94, 343–347.
9. Mirkin, B. L., Clark, S. H. & Zhang, C. (2002) Cell Prolif. 35, 105–115.
10. Li., R, Manella, J., Kong., Y. & Ladisch S. (2000) J. Biol. Chem. 275, 34213–34223
11. Hakomori, S. (2002) Proc. Natl. Acad. Sci. USA 99, 10231–10233.
12. Jacewicz, M., Clausen, H., Nudelman, E., Donohue-Rolfe, A. & Keusch, G. T. (1986)
J. Exp. Med. 163, 1391–1404.
13. Lindberg, C. A., Brown, J. E., Stromberg, N., Westling-Ryd, M., Schultz, J. E. &
Karlson, K. (1987). J. Biol. Chem. 262, 1779–1785.
14. Gordon, J., Challa, A., Levens, J. M., Gregory, C. D., Williams, J. M., Armitage, R. J.,
Cook, J. P., Roberts, L. M. & Lord, J. M. (2000) Cell Death Differ. 7, 785–794.
15. Kovbasnjuk, O., Edidin, M. & Donowitz, M. (2001) J. Cell Sci. 114, 4025–4031.
16. Saiki, I., Murata, J., Nakajima, M., Tokura, S. & Azuma, I. (1990) Cancer Res. 50,
3631–3637.
17. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. & Tuschl, T.
(2001) Nature 411, 494–498.
18. Hoey, D. E., Sharp, L., Currie, C., Lingwood, C. A., Gally, D. L. & Smith, D. G. (2003)
Cell. Microbiol. 5, 85–97.
19. Schnaar, R. L. (1994) Methods Enzymol. 230, 348–370.
20. Schnaar, R. L. & Needham, L. K. (1994) Methods Enzymol. 230, 371–389.
21. Ling, H., Boodhoo, A., Hazes, B., Cummings, M. D., Armstrong, G. D., Brunton, J.
L & Read, R. J. (1998) Biochemistry 37, 1777–1788.
22. Steffensen, R., Carlier, K., Wiels, J., Levery, S. B., Stroud, M., Cedergren, B., Nilsson
Sojka, B., Bennett, E. P, Jersild, C. & Clausen, H. (2000) J. Biol. Chem. 275,
16723–16729.
23. Schu¨ller, S., Frankel, G. & Phillip, A. D. (2004) Cell Microbiol. 6, 289–301.
24. Muller, A., Home, B., Sot, H, Ge, N. F. Catron, D., Buchanan, M. E, McClanahan,
T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) Nature 410, 50–56.
25. Kojima, Y., Fukumoto, S., Furukawa, K., Okajima, T., Wiels, J., Yokoyama, K.,
Suzuki, Y., Urano, T., Ohta, M. & Furukawa, K. (2000) J. Biol. Chem. 275,
15152–15156.
26. Lavie, Y., Cao, H., Volne, A., Lucci, A., Han, T. Y., Geffen, V., Giuliano, A. E. &
Cabot, M. C. (1997) J. Biol. Chem. 272, 1682–1687.
27. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Brenner, C., Larochette, N.,
Prevost, M. C., Alzari, P. M. & Kroemer, G. (1999) J. Exp. Med. 189, 381–394.
28. Ashkenazi, A. & Dixit, V. M. (1998) Science 281, 1305–1308.
29. Park, B. H., Vogelstein, B. & Kinzler, K. W. (2001) Proc. Natl. Acad. Sci. USA 98,
2598–2603.
30. Holgersson, J., Jovell, P. A. & Breimer, M. E. (1991) J. Biochem. (Tokyo) 110, 120–131.
31. LaCasse, E. C., Bray, M. R., Patterson, B., Lim, W. M., Perampalam, S., Radvanyi,
L. G., Keating, A., Stewart, A. K., Buckstein, R., Sandhu, J. S., et al. (1999) Blood 94,
2901–2910.
32. Arab, S., Rutka, J. & Lingwood, C. (1999) Oncol. Res. 11, 33–39.
33. Arab, S., Russel, E. & Chapman, W. B. (1997) Oncol. Res. 9, 553–563.
34. Ohyama, C., Fukushi, Y., Satoh, M., Saitoh, S., Orikasa, S., Nudelman, E., Straud,
M. & Hakomori, S. (1990) Int. J. Cancer 45, 1040–1044.
35. Ohyama, C., Orikasa, S., Kawamura, S., Satoh,M., Saito, S., Fukushi, Y., Levery, S. B.
& Hakomori, S. (1995) Cancer 76, 1043–1050.
19092  www.pnas.orgcgidoi10.1073pnas.0506474102 Kovbasnjuk et al.
